NCT04858529View on ClinicalTrials.gov

Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)

PHASE3RecruitingINTERVENTIONAL
Enrollment

774

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2025

Conditions
Neoadjuvant Therapies for HER2+ Breast Cancer
Interventions
DRUG

investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)

investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)

DRUG

investigator-selected taxane/trastuzumab/pertuzumab (THP)

investigator-selected taxane/trastuzumab/pertuzumab (THP)

Trial Locations (1)

510080

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
lead

Guangdong Provincial People's Hospital

OTHER